WO2002002751A3 - Alteration of cell membrane - Google Patents

Alteration of cell membrane Download PDF

Info

Publication number
WO2002002751A3
WO2002002751A3 PCT/US2001/020946 US0120946W WO0202751A3 WO 2002002751 A3 WO2002002751 A3 WO 2002002751A3 US 0120946 W US0120946 W US 0120946W WO 0202751 A3 WO0202751 A3 WO 0202751A3
Authority
WO
WIPO (PCT)
Prior art keywords
alteration
cell membrane
regulation
proteins
sequences
Prior art date
Application number
PCT/US2001/020946
Other languages
French (fr)
Other versions
WO2002002751A2 (en
Inventor
Haval Shirwan
Original Assignee
Univ Louisville Res Found
Haval Shirwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU1676302A priority Critical patent/AU1676302A/en
Priority to EP01984107A priority patent/EP1299522B1/en
Priority to AT01984107T priority patent/ATE531789T1/en
Priority to JP2002507992A priority patent/JP2004524806A/en
Priority to AU2002216763A priority patent/AU2002216763B2/en
Priority to CA2413237A priority patent/CA2413237C/en
Application filed by Univ Louisville Res Found, Haval Shirwan filed Critical Univ Louisville Res Found
Priority to US10/312,245 priority patent/US7238360B2/en
Publication of WO2002002751A2 publication Critical patent/WO2002002751A2/en
Publication of WO2002002751A3 publication Critical patent/WO2002002751A3/en
Priority to US11/819,080 priority patent/US8076096B2/en
Priority to US13/316,915 priority patent/US8728747B2/en
Priority to US14/280,940 priority patent/US9255133B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/001Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46434Antigens related to induction of tolerance to non-self
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006Modification of the membrane of cells, e.g. cell decoration
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081Purging biological preparations of unwanted cells
    • C12N5/0087Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • Y10S530/816Attached to the carrier via a bridging agent

Abstract

Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.
PCT/US2001/020946 2000-06-30 2001-07-02 Alteration of cell membrane WO2002002751A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP01984107A EP1299522B1 (en) 2000-06-30 2001-07-02 Alteration of cell membrane
AT01984107T ATE531789T1 (en) 2000-06-30 2001-07-02 CELL MEMBRANE CHANGES
JP2002507992A JP2004524806A (en) 2000-06-30 2001-07-02 Changing cell membranes for new functions
AU2002216763A AU2002216763B2 (en) 2000-06-30 2001-07-02 Alteration of cell membrane
CA2413237A CA2413237C (en) 2000-06-30 2001-07-02 Alteration of cell membrane for new functions
AU1676302A AU1676302A (en) 2000-06-30 2001-07-02 Alteration of cell membrane for new functions
US10/312,245 US7238360B2 (en) 2000-06-30 2001-07-02 Alteration of cell membrane with B7
US11/819,080 US8076096B2 (en) 2000-06-30 2007-06-25 Alteration of cell membrane with FasL
US13/316,915 US8728747B2 (en) 2000-06-30 2011-12-12 Alteration of cell membrane for new functions
US14/280,940 US9255133B2 (en) 2000-06-30 2014-05-19 Alteration of cell membrane for new functions using IL-2 and streptavidin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21558000P 2000-06-30 2000-06-30
US60/215,580 2000-06-30

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/312,245 A-371-Of-International US7238360B2 (en) 2000-06-30 2001-07-02 Alteration of cell membrane with B7
US10312245 A-371-Of-International 2001-07-02
US11/819,080 Continuation US8076096B2 (en) 2000-06-30 2007-06-25 Alteration of cell membrane with FasL

Publications (2)

Publication Number Publication Date
WO2002002751A2 WO2002002751A2 (en) 2002-01-10
WO2002002751A3 true WO2002002751A3 (en) 2002-10-03

Family

ID=22803538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020946 WO2002002751A2 (en) 2000-06-30 2001-07-02 Alteration of cell membrane

Country Status (7)

Country Link
US (4) US7238360B2 (en)
EP (1) EP1299522B1 (en)
JP (1) JP2004524806A (en)
AT (1) ATE531789T1 (en)
AU (2) AU1676302A (en)
CA (1) CA2413237C (en)
WO (1) WO2002002751A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927602B2 (en) * 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
JP2004524806A (en) 2000-06-30 2004-08-19 ユニバーシティ オブ ルイビル リサーチ ファウンデーション,インコーポレイティド Changing cell membranes for new functions
US9321992B2 (en) 2002-06-14 2016-04-26 Case Western Reserve University Cell targeting methods and compositions
US7373559B2 (en) * 2003-09-11 2008-05-13 Copan Systems, Inc. Method and system for proactive drive replacement for high availability storage systems
NZ562946A (en) * 2005-04-29 2011-08-26 Univ Louisville Res Found Cell-surface decoration with active agents
EP3130350A1 (en) * 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
EP1973573B1 (en) * 2005-12-08 2013-05-22 University of Louisville Research Foundation, Inc. Methods and compositions for expanding t regulatory cells
WO2007067681A2 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
CA2648030C (en) * 2006-03-27 2018-02-13 Children's Hospital & Regional Medical Center Compositions and methods comprising the use of cell surface displayed homing endonucleases
HUE030139T2 (en) * 2006-12-27 2017-04-28 Univ Emory Compositions and methods for the treatment of infections
JP5520961B2 (en) * 2008-11-28 2014-06-11 エモリー ユニバーシティ Methods for treating infections and tumors
WO2012011113A2 (en) * 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
WO2016205714A1 (en) * 2015-06-19 2016-12-22 University Of Louisville Research Foundation, Inc. Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3828266B1 (en) 2015-07-29 2022-11-23 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2018165547A1 (en) 2017-03-10 2018-09-13 University Of Louisville Research Foundation, Inc. Fasl-engineered biomaterials with immunomodulatory function
EP3798305A4 (en) 2018-04-27 2022-02-09 Aimed Bio Inc. Magnetic-based biopanning method through attachment of magnetic bead to cell
US11504335B2 (en) 2018-06-18 2022-11-22 University Of Kentucky Research Foundation Increased cell retention in diseased site when cells encapsulated in gelatin methacrylate and polyethylene glycol diacrylate hydrogels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017801A2 (en) * 1997-10-03 1999-04-15 Cancer Research Campaign Technology Limited Materials and methods relating to the stimulation of cells
WO2001052664A1 (en) * 2000-01-24 2001-07-26 University Of Louisville Research Foundation, Inc. Immune modulation with death receptor-induced apoptosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
US6071716A (en) * 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
US5470701A (en) * 1993-02-24 1995-11-28 The Regents Of The University Of California Method for determining favorable prognosis in an HIV positive subject using HLA-DR+ /CD38- CD8bright cells
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
JP4435304B2 (en) * 1995-06-29 2010-03-17 イミュネックス・コーポレーション Cytokines that induce apoptosis
CA2230852A1 (en) * 1995-08-30 1997-03-06 The Regents Of The University Of California Therapy for cellular accumulation in chronic inflammatory diseases
GB9523469D0 (en) 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds
WO1997033617A1 (en) 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
US6060054A (en) 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US6042826A (en) * 1996-11-15 2000-03-28 Health Research, Inc. Method for inducing apoptosis of primary central nervous system B cell lymphomas
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
JP2003517311A (en) 1999-12-16 2003-05-27 ユニバーシティ オブ ルイビル リサーチ ファウンデーション,インコーポレイティド Compositions and methods for caspase-induced apoptosis
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
JP2004524806A (en) 2000-06-30 2004-08-19 ユニバーシティ オブ ルイビル リサーチ ファウンデーション,インコーポレイティド Changing cell membranes for new functions
WO2007067681A2 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
EP1973573B1 (en) 2005-12-08 2013-05-22 University of Louisville Research Foundation, Inc. Methods and compositions for expanding t regulatory cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017801A2 (en) * 1997-10-03 1999-04-15 Cancer Research Campaign Technology Limited Materials and methods relating to the stimulation of cells
WO2001052664A1 (en) * 2000-01-24 2001-07-26 University Of Louisville Research Foundation, Inc. Immune modulation with death receptor-induced apoptosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN A ET AL: "Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 JAN 2000, vol. 164, no. 2, 15 January 2000 (2000-01-15), pages 705 - 711, XP002202890, ISSN: 0022-1767 *
DARLING D ET AL: "In vitro immune modulation by antibodies coupled to tumour cells", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 4, no. 12, 1 December 1997 (1997-12-01), pages 1350 - 1360, XP002097146, ISSN: 0969-7128 *
SANO T ET AL: "A STREPTAVIDIN-METALLOTHIONEIN CHIMERA THAT ALLOWS SPECIFIC LABELING OF BIOLOGICAL MATERIALS WITH MANY DIFFERENT HEAVY METAL IONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, March 1992 (1992-03-01), pages 1534 - 1538, XP002938748, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20120213730A1 (en) 2012-08-23
US8728747B2 (en) 2014-05-20
US20150086506A1 (en) 2015-03-26
US20030219419A1 (en) 2003-11-27
ATE531789T1 (en) 2011-11-15
US8076096B2 (en) 2011-12-13
US20090074870A1 (en) 2009-03-19
CA2413237A1 (en) 2002-01-10
EP1299522B1 (en) 2011-11-02
WO2002002751A2 (en) 2002-01-10
US7238360B2 (en) 2007-07-03
AU1676302A (en) 2002-01-14
JP2004524806A (en) 2004-08-19
CA2413237C (en) 2013-09-10
US9255133B2 (en) 2016-02-09
AU2002216763B2 (en) 2007-03-01
EP1299522A2 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
WO2002002751A3 (en) Alteration of cell membrane
WO2000066753A3 (en) Modified vitamin k-dependent polypeptides
WO2001075087A3 (en) Subtilisin variants
WO1998021343A8 (en) Genes encoding telomerase proteins
WO2001011011A3 (en) Multipotent adult stem cells and methods for isolation
DK1210411T3 (en) Compositions and Methods for Improved Cell Culture
WO2002006457A3 (en) Novel lipase genes
WO2000058488A3 (en) Delivery of functional protein sequences by translocating polypeptides
MXPA03001930A (en) Tnf receptor-like molecules and uses thereof.
WO2000056866A3 (en) Akt-3 nucleic acids, polypeptides, and uses thereof
WO2003020892A3 (en) Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
CA2336261A1 (en) Cyclin e2 genes and proteins
WO2000029551A3 (en) Cells, culture methods, and their use in autologous transplantation therapy
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
PT1140023E (en) INTEGRATING COCLEAR FORMULATIONS OF PROTEIN-DNA AND METHODS OF CELLULAR TRANSFORMATION
WO1998055507A3 (en) Modulators of intracellular inflammation, cell death and cell survival pathways containing a card and kinase domain
PT1062336E (en) TNF / NGF RECEPTOR FAMILY RECEIVERS FUNCTION MODULATORS AND OTHER PROTEINS
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
WO2001064912A3 (en) Triazine degrading enzymes
AU2275697A (en) Use of cell membrane permeants in the treatment of cellular proliferative disea ses
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
WO2001000854A3 (en) Chimeric proteins mediating targeted apoptosis
WO2002048187A3 (en) Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2413237

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002216763

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001984107

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001984107

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10312245

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002216763

Country of ref document: AU